Airsculpt Technologies, Inc.AIRS

NasdaqHealthcareServices-Offices & Clinics of Doctors of Medicine
Price (close)
$1.96
Market cap
$140.2M
P/E
—
Revenue (TTM)
$150.7M
Net income
-$11.7M
Dividend yield
—
1-year total return
-73.2%
Net margin
-7.8%
Revenue growth
-8.7%
Debt / equity
0.42x

What Airsculpt Technologies, Inc. does.

Unless otherwise indicated or the context otherwise requires, references in this Annual Report on Form 10-K to the “Company,” “AirSculpt,” “we,” “us” and “our” refer to AirSculpt Technologies, Inc. and its consolidated subsidiaries and the Professional Associations (as defined hereinafter).

AirSculpt is a next-generation body contouring treatment designed to optimize both comfort and precision, available exclusively at AirSculpt offices. The minimally invasive procedure removes fat and tightens skin, while sculpting targeted areas of the body, allowing for quick healing with minimal bruising, tighter skin, and precise results.

We believe our treatment results and elite patient experience have positioned AirSculpt as a preferred body contouring brand. We performed 11,852 body contouring procedures in 2025. Our proprietary and patented AirSculpt ® method is minimally invasive because it requires no needle, no scalpel, no stitches and no general anesthesia to achieve transformational change that appears both natural and smooth. Our patients are guided by surgeons, nurses and patient care consultants through every step of the experience.

Revenue and profit, by fiscal year.

Fiscal year202020212022202320242025
Revenue$62.8M$133.3M$168.8M$195.9M$180.3M$151.8M
Net income$7.6M$10.6M-$14.7M-$4.2M-$8.0M-$11.7M
Free cash flow$10.3M$19.5M$11.5M$14.0M-$2.7M$692,000

More on AIRS.

Figures from Airsculpt Technologies, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.